

Uta Dirksen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4998229/publications.pdf>

Version: 2024-02-01

118
papers

7,814
citations

66234

42
h-index

56606

83
g-index

122
all docs

122
docs citations

122
times ranked

8588
citing authors

#	ARTICLE	IF	CITATIONS
1	⁶⁸ Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the ⁶⁸ Ga-FAPI PET Prospective Observational Trial. <i>Journal of Nuclear Medicine</i> , 2022, 63, 89-95.	2.8	58
2	Etiology, Risk Factors, and Diagnosis of Back Pain in Children and Adolescents: Evidence- and Consensus-Based Interdisciplinary Recommendations. <i>Children</i> , 2022, 9, 192.	0.6	12
3	Proton Therapy for Primary Bone Malignancy of the Pelvic and Lumbar Region – Data From the Prospective Registries ProReg and KiProReg. <i>Frontiers in Oncology</i> , 2022, 12, 805051.	1.3	2
4	Treatment of Unspecific Back Pain in Children and Adolescents: Results of an Evidence-Based Interdisciplinary Guideline. <i>Children</i> , 2022, 9, 417.	0.6	8
5	High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2307-2320.	0.8	24
6	Pain in survivors of Ewing sarcoma: Prevalence, associated factors and prediction of recurrence. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28801.	0.8	1
7	Surgical Treatment for Primary Chest Wall Sarcoma: A Single-Institution Study. <i>Journal of Surgical Research</i> , 2021, 260, 149-154.	0.8	7
8	No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 1550-1557.	1.3	5
9	Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Oncology</i> , The, 2021, 22, e45-e56.	5.1	91
10	<i>NTRK</i> Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets. <i>JCO Precision Oncology</i> , 2021, 5, 450-454.	1.5	2
11	Possible modification of <i>BRSK1</i> on the risk of alkylating chemotherapy-related reduced ovarian function. <i>Human Reproduction</i> , 2021, 36, 1120-1133.	0.4	8
12	Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Oncology</i> , The, 2021, 22, e68-e80.	5.1	37
13	Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Oncology</i> , The, 2021, 22, e57-e67.	5.1	95
14	Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE). <i>Human Reproduction</i> , 2021, 36, 1561-1573.	0.4	20
15	Ewing Sarcoma – Diagnosis, Treatment, Clinical Challenges and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1685.	1.0	101
16	Ewing’s Sarcoma. <i>New England Journal of Medicine</i> , 2021, 384, 1476-1478.	13.9	12
17	Association of treatment delays with an unfavorable outcome in patients with localized Ewing sarcoma: A retrospective analysis of data from the GPOH Euro-E.W.I.N.G.99 trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 11502-11502.	0.8	3
18	Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. <i>Nature Communications</i> , 2021, 12, 3230.	5.8	95

#	ARTICLE	IF	CITATIONS
19	Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2021, 27, 5922-5930.	3.2	14
20	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779.	7.7	110
21	Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study. <i>Cancers</i> , 2021, 13, 4598.	1.7	8
22	Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer. <i>Nature Communications</i> , 2021, 12, 5356.	5.8	11
23	Localized Angiosarcoma, Not One Disease: A Retrospective Single-Center Study on Prognosis Depending on the Primary Site and Etiology. <i>Sarcoma</i> , 2021, 2021, 1-10.	0.7	6
24	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	5.8	237
25	Determinants of utilization of cryopreservation of germ cells in adolescent cancer patients in four European countries. <i>European Journal of Pediatrics</i> , 2020, 179, 51-60.	1.3	10
26	Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma. <i>Molecular Oncology</i> , 2020, 14, 248-260.	2.1	12
27	Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial. <i>Clinical Orthopaedics and Related Research</i> , 2020, 478, 290-302.	0.7	45
28	Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from 18F-FDG-PET/CT and circulating tumor DNA. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1564-1575.	3.3	14
29	Dynamic prediction of overall survival: a retrospective analysis on 979 patients with Ewing sarcoma from the German registry. <i>BMJ Open</i> , 2020, 10, e036376.	0.8	0
30	Pelvic Ewing sarcoma: a retrospective outcome analysis of 104 patients who underwent pelvic tumor resection at a single supra-regional center. <i>Journal of Orthopaedic Surgery and Research</i> , 2020, 15, 534.	0.9	12
31	Seeking international consensus on approaches to primary tumour treatment in Ewing sarcoma. <i>Clinical Sarcoma Research</i> , 2020, 10, 21.	2.3	14
32	Multimodality treatment including surgery for primary pulmonary sarcoma: Size does matter. <i>Journal of Surgical Oncology</i> , 2020, 122, 506-514.	0.8	8
33	Pleuropulmonary Blastoma Misinterpreted as Spontaneous Pneumothorax in an Infant. <i>Annals of Thoracic Surgery</i> , 2020, 110, e79.	0.7	5
34	High Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma. <i>Cancers</i> , 2020, 12, 644.	1.7	16
35	Primary and Metastatic Intracranial Ewing Sarcoma at Diagnosis: Retrospective International Study and Systematic Review. <i>Cancers</i> , 2020, 12, 1675.	1.7	8
36	The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma. <i>Cancers</i> , 2020, 12, 904.	1.7	2

#	ARTICLE	IF	CITATIONS
37	Efficacy of add-on treosulfan and melphalan high-dose therapy in patients with high-risk metastatic Ewing sarcoma: Report from the International Ewing 2008R3 trial.. Journal of Clinical Oncology, 2020, 38, 11501-11501.	0.8	6
38	Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).. Journal of Clinical Oncology, 2020, 38, 11502-11502.	0.8	34
39	Efficacy of maintenance therapy with zoledronic acid in patients with localized Ewing sarcoma: Report from the international Ewing 2008 trial.. Journal of Clinical Oncology, 2020, 38, 11523-11523.	0.8	8
40	Correlation of response with progression-free (PFS) and overall (OS) survival in relapsed/refractory Ewing sarcoma (RR-ES): Results from the rEECur trial.. Journal of Clinical Oncology, 2020, 38, 11524-11524.	0.8	1
41	The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups.. Journal of Clinical Oncology, 2020, 38, LBA10503-LBA10503.	0.8	12
42	Title is missing!. , 2020, 15, e0237792.		0
43	Title is missing!. , 2020, 15, e0237792.		0
44	Title is missing!. , 2020, 15, e0237792.		0
45	Title is missing!. , 2020, 15, e0237792.		0
46	Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model. Pediatric Blood and Cancer, 2019, 66, e27943.	0.8	17
47	Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery. Scientific Reports, 2019, 9, 11000.	1.6	13
48	Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients. EBioMedicine, 2019, 47, 156-162.	2.7	23
49	Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes. Nature Communications, 2019, 10, 4128.	5.8	51
50	High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. Journal of Clinical Oncology, 2019, 37, 3192-3202.	0.8	84
51	DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1â€“NFATc2 fusion from Ewing sarcoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1273-1281.	1.2	50
52	The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma. Cancer Medicine, 2019, 8, 1086-1094.	1.3	14
53	Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma.. Journal of Clinical Oncology, 2019, 37, 11007-11007.	0.8	20
54	Recurrence of Ewing sarcoma: Is detection by imaging followâ€“up protocol associated with survival advantage?. Pediatric Blood and Cancer, 2018, 65, e27011.	0.8	22

#	ARTICLE	IF	CITATIONS
55	The landscape of genomic alterations across childhood cancers. <i>Nature</i> , 2018, 555, 321-327.	13.7	1,068
56	Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. <i>Modern Pathology</i> , 2018, 31, 1246-1256.	2.9	76
57	Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26719.	0.8	39
58	Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 168-179.	0.8	92
59	High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.C.99 and Ewing-2008. <i>Journal of Clinical Oncology</i> , 2018, 36, 3110-3119.	0.8	107
60	Defining a Characteristic Gene Expression Set Responsible for Cancer Stem Cell-Like Features in a Sub-Population of Ewing Sarcoma Cells CADO-ES1. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3908.	1.8	13
61	Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol. <i>BMC Cancer</i> , 2018, 18, 930.	1.1	13
62	PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents. <i>European Journal of Cancer</i> , 2018, 103, 227-237.	1.3	41
63	Impact of Whole Lung Irradiation on Survival Outcome in Patients With Lung Relapsed Ewing Sarcoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 584-592.	0.4	16
64	Ewing sarcoma. <i>Nature Reviews Disease Primers</i> , 2018, 4, 5.	18.1	500
65	Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. <i>Nature Communications</i> , 2018, 9, 3184.	5.8	50
66	Impact of the Interdisciplinary Tumor Board of the Cooperative Ewing Sarcoma Study Group on local therapy and overall survival of Ewing sarcoma patients after induction therapy. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27384.	0.8	22
67	Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27251.	0.8	30
68	Target discovery screens using pooled shRNA libraries and next-generation sequencing: A model workflow and analytical algorithm. <i>PLoS ONE</i> , 2018, 13, e0191570.	1.1	11
69	Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets. <i>Oncotarget</i> , 2018, 9, 1587-1601.	0.8	66
70	Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE). <i>JMIR Research Protocols</i> , 2018, 7, e10824.	0.5	14
71	DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. <i>Nature Medicine</i> , 2017, 23, 386-395.	15.2	193
72	Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells. <i>Oncogene</i> , 2017, 36, 3505-3514.	2.6	153

#	ARTICLE	IF	CITATIONS
73	Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE) Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1704-1712.	10.8	784314
74	Childhood cancer predisposition syndromes: A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1017-1037.	0.7	200
75	Inhibition of the oncogenic fusion protein EWS-FLI1 causes G ₂ -M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma. <i>Science Signaling</i> , 2017, 10, .	1.6	51
76	Ewing sarcoma during follow-up. <i>Nuklearmedizin - Nuclear Medicine</i> , 2017, 56, 233-238.	0.3	4
77	Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1704-1712.	0.8	33
78	Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity. <i>Sarcoma</i> , 2016, 2016, 1-6.	0.7	16
79	Management and Outcome of Ewing Sarcoma of the Head and Neck. <i>Pediatric Blood and Cancer</i> , 2016, 63, 604-610.	0.8	53
80	Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. <i>European Journal of Cancer</i> , 2016, 61, 128-136.	1.3	69
81	Next-generation personalised medicine for high-risk paediatric cancer patients: The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101.	1.3	262
82	Pediatric bone tumors in Germany from 1987 to 2011: incidence rates, time trends and survival. <i>Acta Oncologica</i> , 2016, 55, 1145-1151.	0.8	27
83	Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium. <i>Journal of Clinical Oncology</i> , 2016, 34, 3440-3450.	0.8	173
84	Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2016, 22, 4356-4365.	3.2	68
85	Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease. <i>Molecular Oncology</i> , 2016, 10, 677-692.	2.1	37
86	Impact of gender on efficacy and acute toxicity of alkylating agent-based chemotherapy in Ewing sarcoma: Secondary analysis of the Euro-Ewing99-R1 trial. <i>European Journal of Cancer</i> , 2015, 51, 2453-2464.	1.3	21
87	Gene expression profiling of Ewing sarcoma tumours reveals the prognostic importance of tumour-stromal interactions: a report from the Children's Oncology Group. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 83-94.	1.3	66
88	Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1307-16.	3.3	109
89	Local Control in Ewing Sarcoma of the Chest Wall: Results of the EURO-EWING 99 Trial. <i>Annals of Surgical Oncology</i> , 2015, 22, 2853-2859.	0.7	39
90	Development of Curative Therapies for Ewing Sarcomas by Interdisciplinary Cooperative Groups in Europe. <i>Klinische Padiatrie</i> , 2015, 227, 108-115.	0.2	9

#	ARTICLE	IF	CITATIONS
91	Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. <i>Journal of Clinical Oncology</i> , 2015, 33, 3036-3046.	0.8	516
92	Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2015, 21, 4935-4946.	3.2	68
93	Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function. <i>Oncology Reports</i> , 2014, 32, 845-852.	1.2	20
94	The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1382-1386.	0.8	52
95	Cyclophosphamide Compared With Ifosfamide in Consolidation Treatment of Standard-Risk Ewing Sarcoma: Results of the Randomized Noninferiority Euro-EWING99-R1 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 2440-2448.	0.8	136
96	Long-term follow-up of the CESS 81 and CESS 86 Ewing sarcoma trials.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10529-10529.	0.8	0
97	Stem cell rescue from irradiation of multifocal bone disease combined with high-dose chemotherapy and reduced intensity conditioned haplodisparate stem cell transplantation in advanced pediatric sarcomas: Update of MetaEICESS 2007.. <i>Journal of Clinical Oncology</i> , 2014, 32, e21021-e21021.	0.8	0
98	Management of Bone Tumours in Paediatric Oncology. <i>Clinical Oncology</i> , 2013, 25, 19-26.	0.6	33
99	Impact of gender on efficacy and acute toxicity in standard risk localized (SR) Ewing sarcomas (ES) in the Euro-Ewing99-R1 trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10031-10031.	0.8	1
100	Can postoperative radiotherapy be omitted in localized standard-risk Ewing sarcoma? An observational study of the Euro-EWING Group.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10518-10518.	0.8	5
101	The ganglioside antigen GD2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting. <i>British Journal of Cancer</i> , 2012, 106, 1123-1133.	2.9	112
102	Ewing Sarcoma: Biology-Based Therapeutic Perspectives. <i>Pediatric Hematology and Oncology</i> , 2012, 29, 12-27.	0.3	29
103	No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. <i>Annals of Oncology</i> , 2011, 22, 1614-1621.	0.6	42
104	Risk of recurrence and survival after relapse in patients with Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2011, 57, 549-553.	0.8	228
105	Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology. <i>Journal of Adolescent and Young Adult Oncology</i> , 2011, 1, 118-123.	0.7	2
106	Preliminary Efficacy of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 4534-4540.	0.8	195
107	Primary Disseminated Multifocal Ewing Sarcoma: Results of the Euro-EWING 99 Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 3284-3291.	0.8	429
108	The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). <i>Cancer</i> , 2010, 116, 443-450.	2.0	137

#	ARTICLE	IF	CITATIONS
109	Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases. <i>Bone Marrow Transplantation</i> , 2010, 45, 483-489.	1.3	32
110	Radiation Toxicity Following Busulfan/Melphalan High-dose Chemotherapy in the EURO-EWING-99-trial: Review of GPOH Data. <i>Strahlentherapie Und Onkologie</i> , 2009, 185, 21-22.	1.0	32
111	Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. <i>Journal of Pathology</i> , 2009, 218, 222-231.	2.1	87
112	Whole Lung Irradiation in Patients with Exclusively Pulmonary Metastases of Ewing Tumors. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 193-197.	1.0	72
113	Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy. <i>European Journal of Cancer</i> , 2008, 44, 699-709.	1.3	87
114	Significant Benefit of Multimodal Imaging: PET/CT Compared with PET Alone in Staging and Follow-up of Patients with Ewing Tumors. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1932-1939.	2.8	120
115	Treosulfan high dose therapy with autologous stem cell rescue in high-risk Ewing tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 10039-10039.	0.8	1
116	Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines. <i>Anti-Cancer Drugs</i> , 2006, 17, 657-662.	0.7	24
117	Vaccination with the Heptavalent Pneumococcal Conjugate Vaccine Prevenar [®] Provides Early Protective Antibody Responses in Children after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2005, 106, 84-84.	0.6	0
118	Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. <i>Annals of Oncology</i> , 2000, 11, 1451-1462.	0.6	137